Burzynski Research Institute, Inc.

Equities

BZYR

US1231591058

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:46:28 26/06/2024 pm IST			5-day change	1st Jan Change
0.0443 ^USD	-11.34%		+46.20%	+0.68%

29/05	Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2024	CI
16/01	Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	CI

Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2024

May 30, 2024 at 01:46 am IST

Burzynski Research Institute, Inc. reported earnings results for the full year ended February 29, 2024. For the full year, the company reported net loss was USD 1.34 million compared to USD 0.916292 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2024	30/05	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	17/01	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	13/23/13	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	14/23/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	26/23/26	CI
Burzynski Research Institute, Inc. Enters into A License Agreement with Dr. Stanislaw R. Burzynski	23/23/23	CI
Burzynski Research Institute, Inc. Announces Resignation of Carlton Hazlewood from the Board	07/23/07	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	14/23/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	14/22/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	15/22/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	27/22/27	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	15/22/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2021	16/21/16	CI
Burzynski Research Institute, Inc Announces Board Changes	07/21/07	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2021	25/21/25	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2020	15/21/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2020	16/20/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2020	16/20/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2020	29/20/29	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2019	15/20/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2019	16/19/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2019	16/19/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2019	30/19/30	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2018	15/19/15	CI
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma	14/16/14	CI

Chart Burzynski Research Institute, Inc.

Duration

Period

Chart Burzynski Research Institute, Inc.

More charts

Company Profile

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and are reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BURZYNSKI RESEARCH INSTITUTE, INC.	+0.68%	5.83M
MODERNA, INC.	+19.41%	45.51B
LONZA GROUP AG	+38.65%	39.36B
IQVIA HOLDINGS INC.	-8.62%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research